{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:05:50Z","timestamp":1792188350764,"version":"4.4.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>\n            We evaluated the activity of minocycline and comparator agents against a large number of\n            <jats:named-content content-type=\"genus-species\">Stenotrophomonas maltophilia<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            \u2009=\u20091,289),\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            -\n            <jats:named-content content-type=\"genus-species\">Acinetobacter calcoaceticus<\/jats:named-content>\n            species complex (\n            <jats:italic>n<\/jats:italic>\n            \u2009=\u20091,081), and\n            <jats:named-content content-type=\"genus-species\">Burkholderia cepacia<\/jats:named-content>\n            complex (\n            <jats:italic>n<\/jats:italic>\n            \u2009=\u2009101) isolates collected from 2014 to 2018 from 87 U.S. medical centers spanning all 9 census divisions.\n          <\/jats:p>","DOI":"10.1128\/aac.01154-19","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T10:31:58Z","timestamp":1565951518000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":45,"title":["<i>In Vitro<\/i>\n            Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018"],"prefix":"10.1128","volume":"63","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa College of Medicine, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Manual of clinical microbiology","author":"Carroll KC","year":"2019","unstructured":"Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW. 2019. Manual of clinical microbiology, 12th ed ASM Press, Washington, DC.","edition":"12"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2018.25.3.13"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky279"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv456"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix559"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/ijmm.IJMM_16_236","article-title":"Antibiotic susceptibility pattern of Burkholderia cepacia complex and Stenotrophomonas maltophilia: a 5-year analysis","volume":"35","author":"Bhavana MV","year":"2017","unstructured":"Bhavana MV, Joshi S, Adhikary R, Beena HB. 2017. Antibiotic susceptibility pattern of Burkholderia cepacia complex and Stenotrophomonas maltophilia: a 5-year analysis. Indian J Med Microbiol 35:318\u2013319.","journal-title":"Indian J Med Microbiol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp253"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00893"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70083-0"},{"key":"e_1_3_2_14_2","unstructured":"CDC. 2013. Antibiotic resistance threats in the United States 2013. http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed May 2019."},{"key":"e_1_3_2_15_2","unstructured":"WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed May 2019."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/314699"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01360-13"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0802.010163"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-8579(93)90033-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.09.005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890460044005"},{"key":"e_1_3_2_24_2","volume-title":"Doxycycline package insert","author":"Mylan Pharmaceucticals","year":"2016","unstructured":"Mylan Pharmaceucticals. 2016. Doxycycline package insert. Mylan Pharmaceucticals, Inc., Morgantown, WV."},{"key":"e_1_3_2_25_2","volume-title":"Minocin package insert","author":"The Medicines Company","year":"2015","unstructured":"The Medicines Company. 2015. Minocin package insert. The Medicines Company, Parsippany, NJ."},{"key":"e_1_3_2_26_2","volume-title":"NUZYRA (omadacycline) package insert","author":"Paratek Pharmaceuticals","year":"2018","unstructured":"Paratek Pharmaceuticals. 2018. NUZYRA (omadacycline) package insert. Paratek Pharmaceuticals, Inc., Boston, MA."},{"key":"e_1_3_2_27_2","volume-title":"XERAVA package insert","author":"Tetraphase Pharmaceuticals","year":"2018","unstructured":"Tetraphase Pharmaceuticals. 2018. XERAVA package insert. Tetraphase Pharmaceuticals, Watertown, MA."},{"key":"e_1_3_2_28_2","volume-title":"Tigecycline package insert","author":"Amneal Biosciences","year":"2018","unstructured":"Amneal Biosciences. 2018. Tigecycline package insert. Amneal Biosciences LLC, Bridgewater, NJ."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.03.019"},{"key":"e_1_3_2_30_2","volume-title":"M100Ed29. Performance standards for antimicrobial susceptibility testing; 29th informational supplement","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. M100Ed29. Performance standards for antimicrobial susceptibility testing; 29th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit293"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks084"},{"key":"e_1_3_2_34_2","volume-title":"The Sanford guide to antimicrobial therapy","author":"Antimicrobial Therapy, Inc","year":"2017","unstructured":"Antimicrobial Therapy, Inc. 2017. The Sanford guide to antimicrobial therapy 2017, 47th ed. Antimicrobial Therapy, Inc., Sperryville, VA.","edition":"47"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01154-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01154-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:22:34Z","timestamp":1645478554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01154-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1128\/AAC.01154-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01154-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"2019-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01154-19"}}